Kenneth Schultz

Trethera Corporation

NIH Rank #2670
  • Early Career
  • Diverse Portfolio

NIH Funding · FY2024

Total Funding
$3M
Fiscal year 2024
Grants Awarded
5
Active NIH grants
National Rank
#2,670
Among 57,894 PIs
First NIH Award
2024
Year of first funding

Funding & rank history

NIH funding totals and national rank by fiscal year.

Single fiscal year on record (FY2024): $3M across 5 grants · National rank #2670.

Top grants by award amount

Kenneth Schultz's NIH grant portfolio, ranked by award amount.

  • 1R44AI186534-01R44
    Development of a novel, targeted small molecule inhibitor of the nucleoside salvage pathway through IND enabling studies and translational mouse models for acute disseminated encephalomyelitis (ADEM)
    $1.1M
    award amount
  • 5R44CA281485-02R44
    Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleotide Salvage Pathway to Treat Underserved Tumor Types
    $696.6K
    award amount
  • 4R42EY034397-02R42
    Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Optic Neuritis
    $615.9K
    award amount
  • 5R41AI179213-02R41
    Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Systemic Lupus Erythematosus
    $305.7K
    award amount
  • 5R41AI179191-02R41
    Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Acute Disseminated Encephalomyelitis (ADEM)
    $297.1K
    award amount

Affiliation

Institutions that have administered grants for Kenneth Schultz.

Affiliated with Trethera Corporation (CA).

Career milestones

Key NIH funding milestones over time.

  1. 2024
    First NIH Award
    Trethera Corporation
  2. 2024
    $500K Cumulative Funding
  3. 2024
    $1M Cumulative Funding
  4. 2024
    $2M Cumulative Funding
  5. 2024
    Entered Top 50% Nationally
    Ranked #2670
  6. 2024
    Entered Top 25% Nationally
    Ranked #2670